CAL
SPRY icon

Capital Analysts LLC’s ARS Pharmaceuticals SPRY Stock Holding History

Capital Analysts LLC’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Hold
1,300
– – ﹤0.01% 1292
2026
Q1 		$10K Hold
1,300
– – ﹤0.01% 1260
2025
Q4 		$15K Hold
1,300
– – ﹤0.01% 1163
2025
Q3 		$13K Hold
1,300
– – ﹤0.01% 1157
2025
Q2 		$23K Hold
1,300
– – ﹤0.01% 989
2025
Q1 		$16K Buy
+1,300
New +$15.6K ﹤0.01% 1043

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Analysts LLC's SPRY Position: Q2 2026 in Review

Capital Analysts LLC held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 1,300 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

Capital Analysts LLC first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $23K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Capital Analysts LLC held 1,300 shares of ARS Pharmaceuticals worth $10K as of Q2 2026.
  • Capital Analysts LLC left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1292 holding.
  • Capital Analysts LLC first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Capital Analysts LLC's ARS Pharmaceuticals position peaked at $23K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.